Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12948MR)

This product GTTS-WQ12948MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12948MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ977MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ3864MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ12725MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6712MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ8473MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ13816MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ12752MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-313M32
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW